Dashboard
1
High Management Efficiency with a high ROE of 20.35%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 57.01
3
Poor long term growth as Net Sales has grown by an annual rate of 5.44% over the last 5 years
4
Flat results in Jun 25
5
With ROE of 22.34%, it has a fair valuation with a 3.50 Price to Book Value
6
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
VND 13,466,845 Million (Mid Cap)
16.00
NA
9.71%
-0.53
22.47%
3.37
Revenue and Profits:
Net Sales:
1,184,237 Million
(Quarterly Results - Jun 2025)
Net Profit:
229,288 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.49%
0%
0.49%
6 Months
2.82%
0%
2.82%
1 Year
-5.12%
0%
-5.12%
2 Years
0.69%
0%
0.69%
3 Years
19.86%
0%
19.86%
4 Years
-18.07%
0%
-18.07%
5 Years
-3.04%
0%
-3.04%
DHG Pharmaceutical JSC for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.44%
EBIT Growth (5y)
5.69%
EBIT to Interest (avg)
57.01
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
0.98
Tax Ratio
13.16%
Dividend Payout Ratio
173.53%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
45.64%
ROE (avg)
20.35%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
3.50
EV to EBIT
12.00
EV to EBITDA
10.44
EV to Capital Employed
5.38
EV to Sales
2.37
PEG Ratio
5.59
Dividend Yield
9.86%
ROCE (Latest)
44.85%
ROE (Latest)
22.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
1,184,237.00
1,105,832.20
7.09%
Operating Profit (PBDIT) excl Other Income
283,752.80
229,737.40
23.51%
Interest
6,508.60
3,747.20
73.69%
Exceptional Items
0.00
0.00
Consolidate Net Profit
229,288.00
186,209.90
23.13%
Operating Profit Margin (Excl OI)
214.40%
183.30%
3.11%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 7.09% vs -4.06% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 23.13% vs -26.96% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,884,867.70
5,015,395.00
-2.60%
Operating Profit (PBDIT) excl Other Income
1,031,482.00
1,140,275.40
-9.54%
Interest
24,886.20
29,584.20
-15.88%
Exceptional Items
0.00
0.00
Consolidate Net Profit
753,552.50
1,017,142.80
-25.91%
Operating Profit Margin (Excl OI)
176.40%
209.80%
-3.34%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -2.60% vs 7.26% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -25.91% vs 6.31% in Dec 2023
About DHG Pharmaceutical JSC 
DHG Pharmaceutical JSC
Pharmaceuticals & Biotechnology
DHG Pharmaceutical Joint Stock Company is a Vietnam-based company engaged in the pharmaceutical industry. The Company manufactures and markets pharmaceutical products, vitamins, supplements and cosmetics. Via its subsidiaries, the Company is also involved in packaging printing, herb cultivation, medicinal supplies trading, as well as domestic travel tour and medical clinic operation.
Company Coordinates 
Company Details
288 Bis Nguyen Van Cu, P. An Hoa, Q. Ninh Kieu CAN THO None : None
Registrar Details






